• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

parkerb@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-8333-1926

Prof Belinda Parker

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

101 Scholarly works
31 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Striking the right balance with type I interferon signalling in cancer
    DOI: 10.1038/s41568-026-00915-1
  • 2025

    Journal article

    Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
    DOI: 10.1016/S1470-2045(25)00559-5
  • 2025

    Journal article

    Abstract PR-02: Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance
    DOI: 10.1158/2326-6074.cimm25-pr-02
  • 2025

    Journal article

    2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
    DOI: 10.1016/j.annonc.2025.08.3002
  • 2023

    Research grants (ARC, NHMRC, MRFF)

    Targeting Crosstalk in the Tumour Microenvironment for Precision Cancer Therapy
  • 2023

    Research grants (other domestic)

    Targeting the Hormone-Immune Cell Axis to Prevent Breast Cancer Progression
  • 2019

    Research Grant

    PRECEPT - PRostatE CancEr Prognosis and Treatment
Belinda Parker

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    Abstract P5-10-30: Developing microenvironment-based prognostic biomarkers for early breast cancer
    DOI: 10.1158/1557-3265.sabcs24-p5-10-30
  • 2025

    Journal article

    Abstract P5-08-08: Predicting local recurrence in DCIS treated predominantly without radiation
    DOI: 10.1158/1557-3265.sabcs24-p5-08-08
  • 2024

    Journal article

    The complexity of immune evasion mechanisms throughout the metastatic cascade
    DOI: 10.1038/s41590-024-01960-4
  • 2023

    Journal article

    Interferon-ε is a tumour suppressor and restricts ovarian cancer
    DOI: 10.1038/s41586-023-06421-w
  • 2023

    Conference Proceedings

    AlphaBet: A Phase I/II trial evaluating the combination of Radium-223 and [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
  • 2023

    Journal article

    Investigating the Role of Heparanase in Breast Cancer Development Utilising the MMTV-PyMT Murine Model of Mammary Carcinoma
    DOI: 10.3390/cancers15113062

RECENT PROJECTS

  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Unraveling Metastasis-Specific Immune Niches to Transform Cancer Treatment
  • 2025

    Research grants (other domestic)

    Testing Alternate Therapeutic Strategies for Bone Metastatic Prostate Cancer

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224